Hodgkin lymphoma may start with something as quiet as painless swollen lymph nodes, yet the biology behind the diagnosis is anything but subtle. In the US alone, an estimated 8,570 new cases are expected in 2023, and the staging picture can shift dramatically based on PET CT findings and classic risk markers. This post pulls together the key numbers from symptoms to survival so you can see where the disease often looks straightforward and where it quickly stops being predictable.
Key Takeaways
- The most common initial symptom of Hodgkin lymphoma is painless, enlarged lymph nodes in 70-80% of patients
- B symptoms (fever, night sweats, weight loss >10%) occur in 40% of Hodgkin lymphoma patients at diagnosis
- Mediastinal lymphadenopathy is present in 60-70% of Hodgkin lymphoma cases on chest X-ray
- In 2023, an estimated 8,570 new cases of Hodgkin lymphoma will be diagnosed in the United States
- The age-adjusted incidence rate for Hodgkin lymphoma in the US is 2.6 per 100,000 persons per year (2017-2021)
- Hodgkin lymphoma accounts for approximately 0.5% of all new cancer cases in the US
- 5-year progression-free survival for all Hodgkin lymphoma patients is 88% (US 2013-2019)
- 5-year overall survival rate is 89.4% for Hodgkin lymphoma in the US
- Stage I-II patients have 95% 5-year OS, stage III-IV 81%
- Epstein-Barr virus (EBV) infection is associated with 40-50% of Hodgkin lymphoma cases worldwide
- History of infectious mononucleosis increases Hodgkin lymphoma risk by 3-4 fold
- HIV infection raises the risk of Hodgkin lymphoma by 5-10 times compared to general population
- ABVD chemotherapy regimen is first-line for 85% of Hodgkin lymphoma patients
- Overall response rate to ABVD is 80-90% with complete response in 70-80%
- Involved-site radiation therapy (ISRT) used in 20-30% of early-stage patients post-chemo
Most patients present with painless enlarged nodes, and PET CT staging is highly accurate for Hodgkin lymphoma.
Related reading
01 · Category
Clinical Presentation and Diagnosis25 stats
01
The most common initial symptom of Hodgkin lymphoma is painless, enlarged lymph nodes in 70-80% of patients
02
B symptoms (fever, night sweats, weight loss >10%) occur in 40% of Hodgkin lymphoma patients at diagnosis
03
Mediastinal lymphadenopathy is present in 60-70% of Hodgkin lymphoma cases on chest X-ray
04
Reed-Sternberg cells are pathognomonic and found in 95% of biopsy samples
05
PET-CT scan has sensitivity of 94% and specificity of 90% for staging Hodgkin lymphoma
06
Ann Arbor staging: 70% of patients present with stage I-II disease
07
Erythrocyte sedimentation rate (ESR) >50 mm/hr correlates with poor prognosis in 60% of cases
08
LDH levels are elevated in 40% of newly diagnosed Hodgkin lymphoma patients
09
Nodular sclerosis subtype is most common (70%) and typically presents with cervical/supraclavicular nodes
10
Mixed cellularity subtype seen in 20-25% and often associated with B symptoms in 50%
11
Excisional biopsy is diagnostic in 98% of Hodgkin lymphoma cases
12
CD15+, CD30+ immunostaining confirms classical Hodgkin lymphoma in 90% of cases
13
Pruritus occurs in 10-30% of patients pre-diagnosis
14
Bone marrow involvement at diagnosis in only 5-10% of Hodgkin lymphoma patients
15
Bulky disease (>10 cm) present in 20% of advanced stage cases
16
Flow cytometry shows limited utility as Reed-Sternberg cells are sparse (<1%)
17
Chest pain or cough from mediastinal mass in 25% of nodular sclerosis cases
18
Lymphocyte-depleted subtype rare (1%) and often EBV-associated
19
Interim PET scan after 2 cycles of chemotherapy predicts progression-free survival with 94% accuracy
20
Splenomegaly in 20-30% at diagnosis, hepatomegaly in 5-10%
21
Fine-needle aspiration has 20-30% false negative rate for Hodgkin lymphoma
22
Classical Hodgkin lymphoma (95%) vs. nodular lymphocyte predominant (5%)
23
Fatigue reported in 50% of patients at presentation
24
EBV-encoded RNA (EBER) positive in 40% of classical cases by in situ hybridization
25
Superior vena cava syndrome rare, <1% of cases
Interpretation
Clinical Presentation and Diagnosis Interpretation
While Hodgkin lymphoma often announces itself as a silent, swollen sentinel in the neck, its full clinical story—from pesky fevers to telltale Reed-Sternberg cells and a PET scan's keen eye—is a masterclass in how a single disease can wear many clever, yet ultimately targetable, disguises.
02 · Category
Epidemiology30 stats
01
In 2023, an estimated 8,570 new cases of Hodgkin lymphoma will be diagnosed in the United States
02
The age-adjusted incidence rate for Hodgkin lymphoma in the US is 2.6 per 100,000 persons per year (2017-2021)
03
Hodgkin lymphoma accounts for approximately 0.5% of all new cancer cases in the US
04
The lifetime risk of developing Hodgkin lymphoma is about 1 in 435 for men and 1 in 589 for women in the US
05
Incidence rates of Hodgkin lymphoma are highest among people aged 20-34 years
06
Globally, there were approximately 83,000 new cases of Hodgkin lymphoma in 2020
07
The global age-standardized incidence rate for Hodgkin lymphoma is 1.1 per 100,000 in 2020
08
In Europe, the incidence rate of Hodgkin lymphoma is highest in Northern Europe at 3.5 per 100,000
09
Hodgkin lymphoma has a bimodal age distribution with peaks at 15-34 years and over 55 years
10
Among adolescents and young adults (15-39 years), Hodgkin lymphoma represents 14% of all lymphomas
11
In the US, non-Hispanic whites have the highest incidence rate of Hodgkin lymphoma at 3.0 per 100,000
12
Incidence of Hodgkin lymphoma has declined by 1.2% per year from 2012-2021 in the US
13
In developing countries, Hodgkin lymphoma incidence is lower at 0.7 per 100,000
14
Males have a 1.4 times higher incidence rate of Hodgkin lymphoma than females globally
15
In the UK, there are about 2,100 new cases of Hodgkin lymphoma annually
16
Hodgkin lymphoma mortality in the US is 0.4 per 100,000 (2017-2021)
17
Prevalence of Hodgkin lymphoma survivors in the US is estimated at 226,516 as of 2022
18
In Australia, Hodgkin lymphoma incidence is 3.2 per 100,000
19
Among children under 15, Hodgkin lymphoma accounts for 5% of childhood cancers
20
In Brazil, the incidence rate of Hodgkin lymphoma is 2.1 per 100,000 (2018-2022)
21
Hodgkin lymphoma represents 10% of all lymphomas diagnosed in patients under 30
22
In Japan, Hodgkin lymphoma incidence is notably low at 0.4 per 100,000
23
US mortality from Hodgkin lymphoma declined 3.5% per year from 2012-2021
24
In India, approximately 3,000 new cases of Hodgkin lymphoma per year
25
Hodgkin lymphoma is the 37th most common cancer worldwide by incidence
26
In Canada, incidence rate is 2.8 per 100,000 (2015-2019)
27
Among HIV-positive individuals, Hodgkin lymphoma risk is increased 10-fold
28
In the US, 870 deaths from Hodgkin lymphoma expected in 2023
29
Global 5-year prevalence of Hodgkin lymphoma is 180,000 cases
30
In Sweden, Hodgkin lymphoma incidence peaked at 4.5 per 100,000 in young adults
Interpretation
Epidemiology Interpretation
Though Hodgkin lymphoma is a relatively rare cancer, its distinct pattern of disproportionately striking young adults during their prime, coupled with stark global inequalities in incidence, reminds us that rarity does not equate to insignificance for the thousands diagnosed each year.
03 · Category
Prognosis and Survival24 stats
01
5-year progression-free survival for all Hodgkin lymphoma patients is 88% (US 2013-2019)
02
5-year overall survival rate is 89.4% for Hodgkin lymphoma in the US
03
Stage I-II patients have 95% 5-year OS, stage III-IV 81%
04
International Prognostic Score (IPS) identifies 8% high-risk patients with 60% 5-year PFS
05
Age >45 years halves 5-year survival to 65%
06
EBV-positive tumors have worse prognosis in young adults (HR 1.8)
07
Complete metabolic response on PET post-chemo predicts 95% 5-year PFS
08
Relapsed HL post-ASCT has 20-30% 5-year OS
09
NLPHL has 97% 10-year OS vs. 82% for classical HL
10
Mixed cellularity subtype has 85% 5-year OS, lymphocyte-rich 95%
11
Bulk >10 cm reduces PFS by 20%
12
HIV-positive HL patients have 5-year OS of 50-70% with HAART+therapy
13
10-year OS for early-stage favorable HL is 95%+
14
Albumin <40 g/L in IPS predicts HR 1.3 for failure
15
Second cancers occur in 15-20% of survivors at 20 years
16
Cardiovascular disease risk increased 3-7 fold post-RT in survivors
17
Pediatric HL 10-year EFS 90% with modern therapy
18
Stage IV with extranodal sites: 75% 5-year OS
19
Female gender associated with better OS (HR 0.8)
20
Anemia (Hb <10.5 g/dL) in IPS: HR 1.5 for progression
21
20-year cumulative incidence of breast cancer 12% in female survivors treated <30yo
22
Lymphocyte count <600/uL predicts poor outcome (HR 1.9)
23
Cure rate >80% overall for Hodgkin lymphoma with modern treatment
24
Elderly (>60) 5-year OS only 60% due to comorbidities
Interpretation
Prognosis and Survival Interpretation
Hodgkin lymphoma wears two faces: for most it is a highly curable, almost polite adversary, boasting an overall survival rate near 90%, yet it reveals a sinister, more stubborn nature in a significant minority—older adults, those with high-risk features, or patients who relapse—where survival rates can plummet by half, reminding us that victory, while common, is never guaranteed and often comes with long-term consequences.
More related reading
04 · Category
Risk Factors24 stats
01
Epstein-Barr virus (EBV) infection is associated with 40-50% of Hodgkin lymphoma cases worldwide
02
History of infectious mononucleosis increases Hodgkin lymphoma risk by 3-4 fold
03
HIV infection raises the risk of Hodgkin lymphoma by 5-10 times compared to general population
04
Immunosuppression from organ transplant increases Hodgkin lymphoma risk up to 6-fold
05
Family history of Hodgkin lymphoma confers a 3.1 relative risk if a sibling is affected
06
Smoking is linked to a 1.6-fold increased risk of Hodgkin lymphoma in current smokers
07
EBV-positive Hodgkin lymphoma is more common in developing countries (up to 70%)
08
Obesity (BMI >30) is associated with 1.3 times higher risk of Hodgkin lymphoma
09
First-degree relatives of Hodgkin lymphoma patients have 7-fold increased risk
10
Autoimmune diseases like rheumatoid arthritis increase risk by 2.3-fold
11
Male gender has a relative risk of 1.2-1.5 for Hodgkin lymphoma
12
Young adult age (20-39) has highest population-attributable risk for EBV
13
Celiac disease increases Hodgkin lymphoma risk by 4.7-fold
14
HIV-associated Hodgkin lymphoma often presents at advanced stage (80% stage III/IV)
15
Monozygotic twins have 99-fold increased concordance for Hodgkin lymphoma
16
Alcohol consumption shows inverse association, with 20% risk reduction for moderate drinkers
17
Post-transplant lymphoproliferative disorder includes 20% Hodgkin lymphoma cases
18
Sjögren's syndrome raises risk by 10-fold
19
Pesticide exposure in farmers linked to 1.5-fold risk increase
20
Late EBV infection (after age 10) increases risk due to lack of childhood immunity
21
Systemic lupus erythematosus (SLE) patients have 2.5-fold higher risk
22
Genetic variants in HLA region confer up to 2-fold risk
23
Asbestos exposure associated with 1.8-fold risk in some studies
24
Immunosuppressive therapy post-transplant: azathioprine increases risk 4-fold
Interpretation
Risk Factors Interpretation
While a single common thread weaves through Hodgkin lymphoma—a nexus of immune disruptions from viruses, genetics, and lifestyle—it is striking that your greatest risk may come from your identical twin or a post-transplant drug, yet a modest glass of wine might curiously tilt the odds slightly in your favor.
05 · Category
Treatment23 stats
01
ABVD chemotherapy regimen is first-line for 85% of Hodgkin lymphoma patients
02
Overall response rate to ABVD is 80-90% with complete response in 70-80%
03
Involved-site radiation therapy (ISRT) used in 20-30% of early-stage patients post-chemo
04
Brentuximab vedotin approved for relapsed/refractory Hodgkin lymphoma with 75% response rate
05
Autologous stem cell transplant (ASCT) cures 50% of relapsed patients
06
PD-1 inhibitors like nivolumab achieve 65-70% objective response in relapsed disease
07
For early favorable stage (IA-IIA), 2 cycles ABVD + ISRT yields 95% PFS at 5 years
08
BEACOPP regimen used in advanced disease, with 90% CR rate but higher toxicity
09
Fertility preservation recommended for 70% of patients under 40 before treatment
10
Checkpoint inhibitor pembrolizumab ORR 69% in R/R Hodgkin lymphoma
11
Proton therapy reduces cardiac dose by 50% compared to photon in mediastinal RT
12
AVD + brentuximab vedotin non-inferior to ABVD with less pulmonary toxicity (94% PFS)
13
CAR-T therapy investigational with 50-70% response in early trials for R/R
14
For stage IA NLPHL, rituximab alone achieves 95% CR
15
Dose-attenuated BEACOPP in elderly: 80% PFS with reduced toxicity
16
Maintenance brentuximab post-ASCT improves PFS from 41% to 59% at 3 years
17
Involved-node RT (INRT) standard, reducing volume by 50% vs. older fields
18
Lenalidomide + rituximab ORR 50% in NLPHL relapsed cases
19
Pediatric protocols (e.g., COG) achieve 95% 5-year EFS with response-adapted therapy
20
Allogeneic transplant for multiply relapsed: 20-30% long-term remission
21
Escalated BEACOPP + RT: 92% 5-year OS in advanced HL
22
Nivolumab + AVD ORR 92% in newly diagnosed advanced HL
23
Bleomycin omission safe in low-risk early stage (93% PFS)
Interpretation
Treatment Interpretation
While ABVD knocks Hodgkin lymphoma flat for most, it's the escalating artillery of precision radiation, targeted drugs, and even transplants that keeps the majority standing tall through successive waves of the disease.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Stefan Wendt. (2026, February 13). Hodgkin Lymphoma Statistics. Gitnux. https://gitnux.org/hodgkin-lymphoma-statistics
MLA
Stefan Wendt. "Hodgkin Lymphoma Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/hodgkin-lymphoma-statistics.
Chicago
Stefan Wendt. 2026. "Hodgkin Lymphoma Statistics." Gitnux. https://gitnux.org/hodgkin-lymphoma-statistics.
Sources & references
13 datasets cited across this report · attribution is report-level